GlassScriptPhysician profile
Suraiya Afroz
NPI 1750776266
$2,485.43
in general payments reported to CMS, 2019-2025
12 companies · $562 in 2025
The $562 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $217 · 2020: $31.86 · 2021: $286 · 2022: $376 · 2023: $412 · 2024: $601 · 2025: $562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,575.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,574.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,849.82 | 2020-2025 | Rinvoq, Skyrizi, Humira |
| Amgen INC. | $116.28 | 2022-2025 | Tavneos, Enbrel |
| Celgene Corporation | $113.68 | 2019 | |
| Glaxosmithkline, LLC. | $103.40 | 2019 | |
| Novartis Pharmaceuticals Corporation | $94.45 | 2023-2025 | |
| Ucb, INC. | $60.99 | 2023-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $46.21 | 2021-2025 | Tremfya |
| Lilly USA, LLC | $36.73 | 2024-2025 | Zepbound, Taltz |
| Sandoz INC. | $25.86 | 2024 | Hyrimoz |
| US Oncology Corporate, INC. | $16.61 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $15.89 | 2024 | Orencia |
| Electronic Waveform Lab, INC. | $5.51 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suraiya Afroz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.